Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,069 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (Cohort 3) Clear all
Completed Phase 2 Interventional

Study of NNZ-2566 in Patients With Traumatic Brain Injury

NCT00805818
View directory record Official record
Conditions
Brain Injuries
Interventions
NNZ-2566, Placebo
Drug
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
20
States / cities
Mobile, Alabama • Tucson, Arizona • Colton, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 17, 2026, 4:48 PM EDT
Terminated Phase 1 Interventional

Mesenchymal Stem Cells in Early Rheumatoid Arthritis

NCT03186417
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
2 million hMSC/kg, 4 million hMSC/kg, 6 million hMSC/kg, placebo
Biological
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)

NCT02393417
View directory record Official record
Conditions
Warts
Interventions
CANDIN, Placebo
Biological · Other
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Encinitas, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.

NCT00996268
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
GSK2212836
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

NCT05824091
View directory record Official record
Conditions
Tuberculosis
Interventions
MK-7762 (TBD09), Placebo
Drug · Other
Lead sponsor
Gates Medical Research Institute
Other
Eligibility
19 Years to 55 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

NCT01406418
View directory record Official record
Conditions
Influenza
Interventions
CR6261 2 mg/kg, CR6261 5 mg/kg, CR6261 15 mg/kg, CR6261 30 mg/kg, CR6261 50 mg/kg, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Research Study Investigating Mim8 in People With Haemophilia A

NCT04204408
View directory record Official record
Conditions
Healthy Volunteers, Haemophilia A With or Without Inhibitors
Interventions
NNC0365-3769 (Mim8), Placebo (Mim8)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

NCT01119846
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

NCT01824290
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Tadalafil, Placebo, ERA as specific PAH treatment
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 17, 2026, 4:48 PM EDT
Terminated Phase 1 Interventional

SP16 as a Therapeutic for COVID-19 Induced ARDS

NCT05135624
View directory record Official record
Conditions
SARS CoV 2 Infection, Pneumonia
Interventions
SP16 (6mg), Placebo, SP16 (12 mg)
Drug · Other
Lead sponsor
Serpin Pharma, LLC
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate HT-6184 in Healthy Subjects

NCT05447546
View directory record Official record
Conditions
Normal Healthy Subjects
Interventions
HT-6184, HT-6184 Placebo
Drug
Lead sponsor
Halia Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

LMN-101 in a Campylobacter Human Challenge Model

NCT04182490
View directory record Official record
Conditions
Campylobacter Infections
Interventions
LMN-101, Placebo
Biological · Drug
Lead sponsor
Lumen Bioscience, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

NCT01959594
View directory record Official record
Conditions
Healthy
Interventions
3 mg PF-06412562, 10 mg PF-06412562, 25 mg PF-06412562, PF-06412562 TBD mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

TD-0903 for ALI Associated With COVID-19

NCT04402866
View directory record Official record
Conditions
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
Interventions
TD-0903, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Duarte, California • Denver, Colorado • Sebring, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects

NCT05918588
View directory record Official record
Conditions
Immune System Disorder (Healthy Volunteer)
Interventions
Belumosudil mesylate, Placebo
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 17, 2026, 4:48 PM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

NCT02736656
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 18 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
16
States / cities
Little Rock, Arkansas • Long Beach, California • Colorado Springs, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 17, 2026, 4:48 PM EDT
Terminated Phase 3 Interventional Results available

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT03955146
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT02443116
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
NGM282, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
Chandler, Arizona • Tucson, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age

NCT03303625
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Respiratory Tract Infections
Interventions
Ad26.RSV.preF (1*10^11 vp), Ad26.RSV.preF (5*10^10 vp), Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
12 Months to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Newton, Kansas
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 17, 2026, 4:48 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Niraparib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
24
States / cities
Burbank, California • Duarte, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia

NCT04447989
View directory record Official record
Conditions
Bronchopulmonary Dysplasia of Newborn
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
Christoph Hornik
Other
Eligibility
Up to 29 Weeks
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
25
States / cities
Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 2 Interventional

Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma

NCT01693315
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Eye Disease
Interventions
AMA0076, Placebo
Drug
Lead sponsor
Amakem, NV
Industry
Eligibility
30 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Artesia, California • Inglewood, California • Petaluma, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects

NCT01030315
View directory record Official record
Conditions
Healthy
Interventions
HM10760A or placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
US, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

NCT00357370
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
16
States / cities
Jonesboro, Arkansas • Fresno, California • Greenbrae, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 17, 2026, 4:48 PM EDT